Adalimumab bij perifere spondyloartritis zonder AS of PsA.
Completed
- Conditions
- spondyloartritis, spondylitis ankylosans, artritis psoriatica
- Registration Number
- NL-OMON23446
- Lead Sponsor
- dr Baeten
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 40
Inclusion Criteria
1. Leeftijd 18-70;
2. 3 maanden diagnose perifere spondyloartritis en niet voldoen aan classificatie spondylitis ankylosans;
Exclusion Criteria
1. In 2 maanden voor start behandeling met anti-TNF of andere studie-medicatie;
2. In 4 weken voor start een intra articulaire inject met corticosteroiden;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary objective is to evaluate the efficacy and safety of adalimumab for the treatment of peripheral spondyloarthritis not fulfilling the classification criteria for AS or PsA.
- Secondary Outcome Measures
Name Time Method The secondary objectives of this study are to assess the effect of adalimumab on:<br /><br>1. Function and quality of life;<br /><br>2. Serum biomarkers;<br /><br>3. Synovial biomarkers.